Emerging pharmaceutical therapies for osteoarthritis

Area of Science:

• Rheumatology and Orthopedics
• Pharmacology and Drug Discovery
• Biomedical Engineering

Background:

• Osteoarthritis (OA) prevalence and disease burden are increasing globally, posing a significant public health challenge.
• Current OA treatments lack specificity, highlighting a critical unmet medical need.
• Advances in understanding OA pathophysiology reveal numerous potential therapeutic targets.

Purpose of the Study:

• To review emerging OA therapies targeting structural progression and pain.
• To discuss clinical data and challenges for novel OA drug development.
• To provide context for recent pharmaceutical advancements in OA management.

Main Methods:

• Literature review of pathophysiological processes in OA.
• Analysis of emerging therapeutic targets and their mechanisms.
• Examination of clinical trial data for novel OA treatments.
• Discussion of challenges in developing disease-modifying OA drugs (DMOADs).

Main Results:

• Several promising therapeutic targets are under clinical investigation, including those for matrix-degrading proteases, senescent chondrocytes, cartilage repair, bone remodelling, inflammation, and Wnt signalling.
• Novel approaches for OA-related pain, such as nerve growth factor inhibitors, are also being explored.
• These emerging therapies are poised to significantly alter OA management strategies.

Conclusions:

• Emerging therapies targeting specific OA pathophysiological pathways offer new hope for patients.
• Further research and clinical trials are crucial to overcome challenges in developing effective disease-modifying OA drugs (DMOADs).
• The landscape of OA treatment is expected to be transformed by these advancements in the near future.